Imidazoline receptor I₁ (I₁)

The Imidazoline receptor I₁ is a distinct signaling protein located primarily in the rostral ventrolateral medulla (RVLM) of the brainstem and the renal tubules [1][2]. It is a key regulator of the sympathetic nervous system; its activation leads to a reduction in sympathetic outflow, resulting in decreased peripheral vascular resistance and lowered blood pressure [3]. The protein Nischarin (NISCH) is widely recognized as the molecular basis for the I₁ imidazoline binding site [4]. Selective I₁ receptor agonists, such as moxonidine and rilmenidine, are used clinically as second-generation antihypertensive agents because they offer similar efficacy to older drugs like clonidine but with significantly fewer sedative side effects [5]. In addition to cardiovascular regulation, the I₁ receptor is involved in sodium excretion in the kidneys and has been linked to the modulation of insulin sensitivity and glucose metabolism [6]. The receptor's signaling pathway involves the activation of phosphatidylcholine-selective phospholipase C and the subsequent release of diacylglycerol and arachidonic acid [1]. This target remains a significant area of interest for treating conditions characterized by sympathetic overactivity, such as metabolic syndrome and chronic kidney disease [6].

Other names

I1 receptorImidazoline-1 receptorNischarinNISCHI1-imidazoline receptor

Agonism of I₁ receptors in the rostral ventrolateral medulla (RVLM) inhibits sympathetic outflow, leading to a reduction in peripheral vascular resistance and blood pressure [1][3].